Berenberg Bank analyst Scott Bardo maintained a Buy rating on Qiagen (QGEN) today and set a price target of EUR35.00. The company’s shares closed last Monday at $40.56, close to its 52-week high of $41.55.
According to TipRanks.com, Bardo is a 5-star analyst with an average return of 16.8% and a 76.9% success rate. Bardo covers the Healthcare sector, focusing on stocks such as Siemens Healthineers AG, Tecan Group AG, and LivaNova.
Qiagen has an analyst consensus of Moderate Buy, with a price target consensus of $35.13, which is a -6.8% downside from current levels. In a report issued on November 14, J.P. Morgan also upgraded the stock to Buy with a $40.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $41.55 and a one-year low of $25.04. Currently, Qiagen has an average volume of 1.92M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services.
